Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on MRNS. EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research report on Monday, September 23rd. Royal Bank of Canada dropped their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research report on Friday, October 25th. Finally, HC Wainwright reissued a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Marinus Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Trading Up 0.2 %

MRNS stock opened at $0.54 on Monday. The stock has a market capitalization of $29.82 million, a P/E ratio of -0.22 and a beta of 1.03. The firm has a 50-day moving average price of $0.36 and a 200-day moving average price of $1.00. Marinus Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $10.50.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its position in shares of Marinus Pharmaceuticals by 1,968.5% during the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 126,752 shares during the last quarter. Franklin Resources Inc. increased its position in Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after purchasing an additional 1,219,871 shares during the period. World Investment Advisors LLC bought a new position in Marinus Pharmaceuticals during the 3rd quarter worth approximately $104,000. Jacobs Levy Equity Management Inc. raised its holdings in Marinus Pharmaceuticals by 39.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares during the last quarter. Finally, Suvretta Capital Management LLC lifted its position in shares of Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after purchasing an additional 1,253,901 shares during the period. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.